Navigation Links
Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University
Date:1/13/2009

UPPSALA, Sweden, January 13 /PRNewswire/ -- Beactica AB, the Swedish fragment-based drug discovery company, today announced a new research collaboration agreement with GE Healthcare (Chalfont St. Giles, UK), the world leading provider of molecular interaction analysis tools, and Uppsala University (Sweden). The collaboration combines Beactica's unique approach to fragment-based drug discovery and GE Healthcare's Biacore(TM) technology with enzymology expertise from Uppsala University.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090113/333930 )

Under the terms of the agreement, the consortium will collaborate to develop the next generation of Biacore(TM) surface plasmon resonance instruments and applications for fragment-based drug discovery. The project also aims to identify novel high-quality leads against a clinically important, undisclosed protein target from Beactica's discovery pipeline. Financial terms of the agreement were not disclosed.

"We look forward to deepening our relationship with GE Healthcare and Uppsala University," said Beactica's CEO, Dr Per Kallblad. "The Biacore technology is a core component of our kinetics-integrated lead discovery platform. Being an active part in the development of next - generation applications from GE Healthcare will enable us to stay at the forefront of our field."

About Beactica

Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics. The company was spun out of Uppsala University in August 2006. As well as building collaborations with external companies, Beactica is progressing its own drug discovery programmes of small molecule therapeutics. For more information about Beactica, please visit http://www.beactica.com.

For further information, please contact Dr Per Kallblad, CEO Beactica, +46(0)18-560880.


'/>"/>
SOURCE Beactica AB
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
2. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
3. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
4. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
5. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
6. ProUroCare Medical Inc. Announces Pricing of Equity Offering
7. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
8. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
9. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
10. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
(Date:5/25/2016)... India , May 25, 2016 ... Animation Market by Type (3D, 2D, 4D), by Therapeutic ... Education), by End User (Medical Device Manufacturers, Hospitals/ Clinics) ... studies the global Medical Animation Market for the forecast ... to reach USD 301.3 Million by 2021 from USD ...
(Date:5/25/2016)... According to market research "Global ... Demand Forecast to 2022 - Industry Insights by Type ... by P&S Market Research, the global insulin delivery device ... it is expected to grow at a CAGR of ... segment is expected to witness the fastest growth at ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... May 28, 2016 , ... May 26, 2016- In search of the ... with theme event of “K Warriors” on June 4, 2016 at Ashbury Hotel and ... event is sponsored and hosted by Shaolin Institute and sanctioned by KSF (Kungfu Sanda ...
(Date:5/27/2016)... ... , ... Two director-level employees of Horizon Blue Cross Blue Shield of New ... honorees. The award recognizes businesswomen who excel in their fields and who have ... MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and Theresa Ponton, ...
(Date:5/27/2016)... ... May 27, 2016 , ... An educational campaign aimed ... human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It also provides insight ... and industry leaders such as Bioness. , As patients feel increasingly concerned ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... to students studying complementary medicine. Allison Outerbridge is this year’s Life University ... on May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge is ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... with discovery of thousands of defective respirators, according to court documents and SEC ... case of William and Becky Tyler v. American Optical Corporation, Case No. BC588866, ...
Breaking Medicine News(10 mins):